Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity

Blood

Volumn 123, Issue 1, 2014, Pages 15-25

  Hossain, Dewan Md Sakib ^a   Dos Santos, Cedric ^a   Zhang, Qifang ^a   Kozlowska, Anna ^a,b   Liu, Hongjun ^a   Gao, Chan ^a   Moreira, Dayson ^a   Swiderski, Piotr ^a   Jozwiak, Agnieszka ^a   Kline, Justin ^c   Forman, Stephen ^a   Bhatia, Ravi ^a   Kuo, Ya Huei ^a   Kortylewski, Marcin ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; SMALL INTERFERING RNA; STAT3 PROTEIN; TOLL LIKE RECEPTOR 9; TUMOR ANTIGEN; GAMMA INTERFERON; STAT3 PROTEIN, MOUSE; TLR9 PROTEIN, MOUSE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CPG ISLAND; DRUG EFFICACY; EFFECTOR CELL; IMMUNE RESPONSE; IMMUNOGENICITY; LEUKEMIA CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; UPREGULATION; ANIMAL; C57BL MOUSE; CYTOLOGY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; KNOCKOUT MOUSE; LEUKEMIA; METABOLISM; NONOBESE DIABETIC MOUSE; SCID MOUSE; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CPG ISLANDS; GENE EXPRESSION REGULATION, LEUKEMIC; GENE SILENCING; IMMUNE TOLERANCE; INTERFERON-GAMMA; LEUKEMIA; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MICE, TRANSGENIC; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTOR 9;

EID: 84891769689     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-517987     Document Type: Article

References (51)

1. Anguille S, van Tendeloo VF, Berneman ZN Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia. 2012; 26(10): 2186-2196.
2. Topalian SL, Weiner GJ, Pardoll DM Cancer immunotherapy comes of age. J Clin Oncol. 2011; 29(36): 4828-4836.
3. Berthon C, Driss V, Liu J., et al In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother. 2010; 59(12): 1839-1849.
4. Ustun C, Miller JS, Munn D.H., Weisdorf DJ, Blazar BR Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood. 2011; 118(19): 5084-5095.
5. Norde WJ, Hobo W, van der Voort R, Dolstra H. Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood. 2012; 120(4): 728-736.
6. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3(2): 133-146. (Pubitemid 37328691)
7. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 2004; 4(2): 97-105. (Pubitemid 38198738)
8. Benekli M, Baumann H, Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol. 2009; 27(26): 4422-4432.
9. Redell MS, Ruiz MJ, Alonzo T.A., Gerbing RB, Tweardy DJ Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011; 117(21): 5701-5709.
10. Steensma DP, McClure RF, Karp J.E., et al JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia. 2006; 20(6): 971-978. (Pubitemid 43797287)
11. Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008; 18(2): 254-267. (Pubitemid 351206162)
12. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9(11): 798-809.
13. Passamonti F, Maffioli M, Caramazza D. New generation small-molecule inhibitors in myeloproliferative neoplasms. Curr Opin Hematol. 2012; 19(2): 117-123.
14. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4): 252-264.
15. Kortylewski M, Kujawski M, Herrmann A., et al Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res. 2009; 69(6): 2497-2505.
16. Krieg AM. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther. 2012; 22(2): 77-89.
17. Spaner DE, Foley R, Galipeau J., Bramson J. Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. Oncogene. 2008; 27(2): 208-217.
18. Kortylewski M, Swiderski P, Herrmann A., et al In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol. 2009; 27(10): 925-932.
19. Lee H, Deng J, Kujawski M., et al STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med. 2010; 16(12): 1421-1428.
20. Zhang Q, Hossain DM, Nechaev S, et al TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood. 2013; 121(8): 1304-1315.
21. Kuo YH, Landrette SF, Heilman S.A., et al Cbf beta-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia. Cancer Cell. 2006; 9(1): 57-68. (Pubitemid 43069511)
22. Landrette SF, Madera D, He F., Castilla LH The transcription factor PlagL2 activates Mpl transcription and signaling in hematopoietic progenitor and leukemia cells. Leukemia. 2011; 25(4): 655-662.
23. Zhang L, Chen X, Liu X., Kline DE, Teague RM, Gajewski TF, Kline J. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest. 2013; 123(5): 1999-2010.
24. Kortylewski M, Kujawski M, Wang T., et al Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005; 11(12): 1314-1321. (Pubitemid 41752912)
25. Benekli M, Xia Z, Donohue K.A., et al Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood. 2002; 99(1): 252-257.
26. Bonnet D, Dick JE Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3(7): 730-737. (Pubitemid 27298715)
27. Herrmann A, Kortylewski M, Kujawski M., et al Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res. 2010; 70(19): 7455-7464.
28. Nechaev S, Gao C, Moreira D., et al Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape. J Control Release. 2013; 170(3): 307-315.
29. Boyer MW, Waller EK, Bray R.A., et al Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells. Leukemia. 2000; 14(3): 412-418. (Pubitemid 30142864)
30. Mohty M, Olive D, Gaugler B. Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts. Leukemia. 2002; 16(11): 2197-2204. (Pubitemid 35331834)
31. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009; 114(8): 1545-1552.
32. Bui JD, Uppaluri R, Hsieh C.S., Schreiber RD Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res. 2006; 66(14): 7301-7309. (Pubitemid 44197712)
33. Chakraborty A, White SM, Schaefer T.S., Ball ED, Dyer KF, Tweardy DJ Granulocyte colony-stimulating factor activation of Stat3 alpha and Stat3 beta in immature normal and leukemic human myeloid cells. Blood. 1996; 88(7): 2442-2449. (Pubitemid 26327492)
34. Cheng F, Wang HW, Cuenca A, et al A critical role for Stat3 signaling in immune tolerance. Immunity. 2003; 19(3): 425-436. (Pubitemid 37153418)
35. Wang T, Niu G, Kortylewski M., et al Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004; 10(1): 48-54. (Pubitemid 38524698)
36. Nefedova Y, Cheng P, Gilkes D., Blaskovich M, Beg AA, Sebti S.M., Gabrilovich DI. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol. 2005; 175(7): 4338-4346. (Pubitemid 41361968)
37. Cohen PA, Koski GK, Czerniecki B.J., et al STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood. 2008; 112(5): 1832-1843.
38. Mohty M, Isnardon D, Blaise D., et al Identification of precursors of leukemic dendritic cells differentiated from patients with acute myeloid leukemia. Leukemia. 2002; 16(11): 2267-2274. (Pubitemid 35331843)
39. Kadowaki N, Kitawaki T. Recent advance in antigen-specific immunotherapy for acute myeloid leukemia. Clin Dev Immunol. 2011; 2011: 104926.
40. Delale T, Paquin A, Asselin-Paturel C, et al MyD88-dependent and -independent murine cytomegalovirus sensing for IFN-alpha release and initiation of immune responses in vivo. J Immunol. 2005; 175(10): 6723-6732. (Pubitemid 41598916)
41. Topalian SL, Drake CG, Pardoll DM Targeting the PD-1/B7-H1(PD-L1) pathway to activate antitumor immunity. Curr Opin Immunol. 2012; 24(2): 207-212.
42. Saudemont A, Quesnel B. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood. 2004; 104(7): 2124-2133. (Pubitemid 39297867)
43. Zhou Q, Munger ME, Highfill S.L., et al Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood. 2010; 116(14): 2484-2493.
44. Zhou Q, Munger ME, Veenstra R.G., et al Coexpression of Tim-3 and PD-1 identifies a CD81 T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011; 117(17): 4501-4510.
45. Marzec M, Zhang Q, Goradia A., et al Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA. 2008; 105(52): 20852-20857.
46. Wölfle S.J., Strebovsky J, Bartz H., et al PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol. 2011; 41(2): 413-424.
47. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008; 14(3): 109-119.
48. Sanchez-Correa B., Bergua JM, Campos C, et al Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine. 2013; 61(3): 885-891.
49. Quezada SA, Peggs KS, Curran M.A., Allison JP CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006; 116(7): 1935-1945. (Pubitemid 44033317)
50. Huang B, Zhao J, Unkeless J.C., Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene. 2008; 27(2): 218-224.
51. Väisänen MR, Väisänen T, Jukkola-Vuorinen A, et al. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. Prostate. 2010; 70(8): 817-824.